Cytokinetics, Incorporated (NASDAQ: CYTK) announced new clinical data for MYQORZO (aficamten) at the European Society of Cardiology Heart Failure 2026 Congress. The presentations included analyses from three clinical trials: SEQUOIA-HCM, MAPLE-HCM, and FOREST-HCM.

Data from the MAPLE-HCM trial showed aficamten outperformed metoprolol, a beta-blocker, across all treatment doses in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The analysis demonstrated significant improvements in exercise capacity, outflow gradients, and N-terminal pro-B-type natriuretic peptide levels with aficamten, while metoprolol showed no improvement regardless of dose.

A secondary analysis examined sex differences in MAPLE-HCM, showing that despite women entering the trial with more severe baseline characteristics, MYQORZO delivered nearly identical improvements in peak oxygen consumption for both sexes, with increases of 2.2 mL/kg/min.

Long-term safety data from the FOREST-HCM trial tracked 122 patients for up to 96 weeks. The analysis found that MYQORZO treatment did not increase the incidence of arrhythmias, including among 16 patients who discontinued beta-blocker therapy during aficamten treatment.

An open-label extension study in Chinese patients showed aficamten was well tolerated through 48 weeks of treatment. Patients experienced no serious or severe treatment-emergent adverse events and showed significant improvements in cardiac measurements and functional capacity scores.

Additional data from SEQUOIA-HCM provided analysis of aficamten's effect on left atrial mechanics in oHCM patients. Among 269 patients, aficamten significantly improved left atrial reservoir strain and reduced left atrial volume index compared with placebo.

The company also presented real-world evidence data highlighting the clinical and economic burden of HCM across different patient populations, including pediatric patients.

MYQORZO is approved in the United States, China and European Union for treating symptomatic obstructive hypertrophic cardiomyopathy in adults.